1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
Pro Medicus (ASX:PME) secures $29 million in new US contracts across varied segmentsCurrent US market share is just above 10%, with ongoing growth potentialAI plays a central role in enhancing efficiency and supporting radiologist workloadsShare price weakness seen as part of broader market rotation, not reflective of company performance
Pro Medicus (ASX:PME) has maintained its upward momentum, marked by three new contracts valued at $29 million across diverse segments in the US market. CEO Dr Sam Hupert underlines the reach of these wins, which include agreements with a specialist paediatric hospital in Alabama, the first pure cancer treatment hospital in Buffalo, New York, and a doctor-managed regional centre in southwest Washington. According to Hupert, this demonstrates the expanding client base, moving beyond major institutions to encompass medium and smaller entities.
Hupert notes that the US healthcare imaging market is substantial, with approximately 617 million tests annually. Pro Medicus currently holds a share just above 10%. The sales pipeline remains robust, having announced $273 million in contracts this financial year. Hupert identifies the upcoming Radiological Society of North America conference as a vital prospecting event, likely to provide further lead generation and opportunities.
The rapid integration of AI within Pro Medicus platforms is highlighted by Hupert, who sees AI as an enabler for efficiency and quality in radiology, especially amid acute radiologist shortages in the US. Retention of long-term clients and a record of contract renewals are attributed to the high level of customer loyalty and complex implementation. Hupert considers recent share price movements as sector-wide, rather than company-specific.
